Kenya’s new HIV prevention pill: Can local manufacturing change healthcare?
Kenya has been selected to manufacture an investigational once-monthly HIV prevention pill — raising larger questions about the country’s pharmaceutical future
By Collins Kibet
Kenya was yesterday selected as one of three African countries preparing to manufacture alimatravir, an investigational once-monthly oral pill being developed to prevent HIV infection. The development matters not only because of the medicine itself, but because Kenya is being positioned on the production side of an important health innovation rather than simply waiting to receive imported supplies.
Alimatravir is being developed as a form of pre-exposure prophylaxis, commonly known as PrEP. Unlike daily oral PrEP, the medicine is designed to be taken once a month. If clinical trials confirm its safety and effectiveness and regulators approve it, the medicine could provide another prevention option for people who find daily medication difficult to maintain. There is, however, an important reality that cannot be overlooked: alimatravir is still investigational. It is currently in Phase 3 clinical development and has not yet been approved for general use. Its future will depend on the results of ongoing trials and subsequent regulatory review.
For Kenya, the significance goes beyond HIV prevention. Universal Corporation Limited, a Kenyan pharmaceutical manufacturer, is among the generic manufacturers selected under voluntary licensing arrangements announced by Merck. The licences cover potential production for 129 low- and middle-income countries, subject to successful development and regulatory approval. This could give Kenya an opportunity to strengthen its local pharmaceutical manufacturing capacity while potentially contributing to medicine supply across other developing countries.
For decades, African healthcare systems have depended heavily on imported medicines and medical supplies. Kenya itself still produces only a fraction of the medicines required to meet domestic demand. The World Health Organization has highlighted the need for Kenya to strengthen local manufacturing of health products and technologies. The alimatravir arrangement therefore raises a much bigger question: can Kenya use this opportunity to build a pharmaceutical industry capable of producing more essential medicines locally?
One of the most important questions for ordinary Kenyans will be affordability. Reports indicate that alimatravir could potentially be supplied to national health systems for around US$5, or roughly KSh650, per person per year. This, however, is a projected future price and should not be confused with a current retail figure. The medicine must first successfully complete clinical development and receive regulatory approval. If the anticipated pricing becomes achievable, affordable manufacturing could help expand access to HIV prevention, particularly in countries where healthcare resources remain limited.
Affordable production does not, however, automatically guarantee affordable healthcare. The medicine would still require effective procurement, distribution, financing and healthcare infrastructure. Kenya would also have to ensure that it reaches the populations most in need of HIV prevention services. Public awareness would remain equally important, because even the most advanced medicine cannot deliver meaningful public-health impact if people do not know about it or cannot access it.
The development could also carry significant implications for employment and industrialisation. Pharmaceutical manufacturing requires scientists, pharmacists, laboratory technicians, engineers, quality-control specialists, logistics professionals and other skilled workers. Expanding domestic production could therefore create employment opportunities while strengthening Kenya’s industrial base, and could encourage further investment in research, technology and specialised manufacturing skills.
These developments come as Kenya is already pursuing a broader strategy to expand local production of medicines and other health products. This year, the country launched its Health Products and Technologies Local Manufacturing Strategy for 2026–2030, aimed at strengthening domestic production and reducing reliance on imported health products. The alimatravir manufacturing arrangement could therefore become part of a wider effort to make Kenya more self-reliant in healthcare manufacturing.
Could Kenya eventually become a regional pharmaceutical manufacturing hub? The licensing arrangement involving manufacturers in Kenya, Uganda and South Africa potentially opens a pathway for African production to serve a large number of low- and middle-income countries. But becoming a pharmaceutical hub requires more than establishing factories. Kenya would need reliable electricity, modern laboratories, skilled personnel, strong regulatory institutions, adequate financing, efficient transport systems and predictable markets. Above all, medicines must consistently meet rigorous safety and quality standards.
Kenya’s role is also significant because the country is involved in clinical research surrounding the medicine. The Kenya Medical Research Institute is participating in late-stage research involving young women in Kenya, Uganda and South Africa. Kenyan researchers are therefore contributing directly to the evidence that will determine whether the medicine can eventually be approved. Kenya is potentially participating across several stages of the process — from research through manufacturing and, eventually, distribution.
It would, however, be premature to describe alimatravir as a solution to Kenya’s HIV challenge. HIV prevention requires a combination of approaches, including testing, counselling, condoms, existing PrEP options, treatment programmes and public-health education. Alimatravir, if eventually approved, would become one additional tool rather than a replacement for existing prevention and treatment strategies.
Kenya must also ensure that enthusiasm surrounding the announcement does not outpace the scientific evidence. Alimatravir remains under investigation, and its widespread use depends on successful clinical trials and regulatory approval. That distinction is particularly important because promising medicines must undergo rigorous scientific evaluation before they can become part of routine healthcare.
Perhaps the bigger opportunity lies beyond one HIV prevention pill. Kenya has a chance to demonstrate that African countries can participate meaningfully in the research, development and manufacturing of medicines rather than remaining primarily consumers of products manufactured elsewhere. If successful, the experience could help build skills, attract investment, strengthen local pharmaceutical companies and contribute to greater long-term health security.
The real test, however, will be whether the opportunity translates into tangible benefits for ordinary Kenyans. Can Kenya produce medicines that are safe, affordable and accessible? Can local manufacturing reduce dependence on imports without compromising quality? Can pharmaceutical investment create meaningful employment and technological development? And can Kenya eventually manufacture a wider range of essential medicines for its own population and the broader African market?
Kenya’s new role in the potential manufacture of alimatravir therefore represents more than a story about a single HIV prevention pill. It is a test of the country’s ambitions in healthcare, science and manufacturing. The medicine must still pass through clinical trials and regulatory approval, but the manufacturing agreement has already opened an important conversation about Kenya’s place in Africa’s pharmaceutical future.
The answer to whether local manufacturing can change healthcare in Kenya will depend not simply on whether the country can produce a new HIV prevention pill, but on whether it can turn that manufacturing capacity into a sustainable system delivering safe, affordable and accessible medicines to the people who need them most.
Similar Posts by The Mt Kenya Times:
- Emirates Holidays and KATA sign deal to boost Kenyan outbound travel
- The rains are coming: Is Kenya ready for what comes with them?
- Road safety awareness programme
- We must prepare for El Niño’s health fallout
- Ngula takes Harambee Stars pay row to tribunal
About the Author
